FGFR2 and intrahepatic cholangiocarcinoma: Meanwhile, a phase III clinical trial comparing FGFR inhibitors with first-line chemotherapy for ICC patients with FGFR2 fusions is ongoing, which is expected to revolutionize the clinical treatment of ICC patients with FGFR2 fusions.